Neoadjuvant Pembrolizumab Shows Promise for Cisplatin-Ineligible MIBC
There is an unmet need for systemic treatment options in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based neoadjuvant chemotherapy, according to investigators.